For HAS3 it concerns OS and PFS of patients with endometrioid ovarian cancer and OS and PFS of patients in grading I. Due to the small number of cases, false tendencies could arise. This evidence concerns the gene HAS3 and ovarian endometrioid adenocarcinoma.